At the news
? BULLISHIMPACT 6/10 6-K filed Jul 28, 2026 at 13:03 ET
GSK's licensor Hansoh Pharma announced positive Phase III results for risvutatug rezetecan (Ris-Rez) in relapsed osteosarcoma, meeting the primary endpoint of progression-free survival. This is the second positive Phase III readout for Ris-Rez, following recent pivotal data in small-cell lung cancer, and strengthens the asset's late-stage profile. The news is a positive pipeline catalyst for GSK's oncology program, though Ris-Rez is still in development and not yet generating revenue, limiting near-term financial impact.
- Hansoh Pharma's ARTEMIS-011 Phase III trial of Ris-Rez met its primary endpoint of progression-free survival in relapsed osteosarcoma.
- Ris-Rez is the only B7-H3-targeted ADC to deliver positive Phase III outcomes across multiple tumor types (osteosarcoma and SCLC).
- GSK holds exclusive global rights to develop and commercialize Ris-Rez outside mainland China, Hong Kong, Macau, and Taiwan.
- Ris-Rez has US FDA Breakthrough Therapy Designation in relapsed or refractory osteosarcoma and relapsed/refractory extensive-stage SCLC.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access